Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Hemodialysis Use and Practice Patterns: An International Survey Study

    American Journal of Kidney Diseases Date published:

  • Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program

    Endocrinology, Diabetes & Metabolism Date published:

  • Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

    Diabetes, Obesity and Metabolism Date published:

  • The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

    Kidney International Date published:

  • Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

    Metabolism Date published:

  • An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

    International Journal of Cardiology Date published:

  • Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

    Clinical Journal of the American Society of Nephrology Date published:

  • Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

    ESC Heart Failure Date published:

  • Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

    Kidney International Reports Date published:

  • Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

    American Journal of Kidney Diseases Date published:

  • Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

    Clinical Pharmacology & Therapeutics Date published:

  • Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial

    Date published:

  • A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

    Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    Date published:

  • Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial

    Date published:

  • ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS

    Date published: